TY  - GEN
AU  - Gutierrez, Antonio
AU  - Bento, Leyre
AU  - Diaz-Lopez, Antonio
AU  - Barranco, Gilberto
AU  - Garcia Recio, Marta
AU  - Lopez-Guillermo, Armando
AU  - Dlouhy, Ivan
AU  - Rovira, Jordina
AU  - Rodriguez, Mario
AU  - Sanchez Pina, Jose Maria
AU  - Baile, Monica
AU  - Martin, Alejandro
AU  - Novelli, Silvana
AU  - Sancho, Juan-Manuel
AU  - Garcia, Olga
AU  - Salar, Antonio
AU  - Bastos-Oreiro, Mariana
AU  - Rodriguez-Salazar, Maria Jose
AU  - Fernandez, Ruben
AU  - de la Cruz, Fatima
AU  - Queizan, Jose Antonio
AU  - Gonzalez de Villambrosia, Sonia
AU  - Cordoba, Raul
AU  - Lopez, Andres
AU  - Luzardo, Hugo
AU  - Garcia, Daniel
AU  - Sastre-Serra, Jorge
AU  - Garcia, Juan Fernando
AU  - Montalban, Carlos
AU  - Cabanillas, Fernando
AU  - Rodriguez, Jose
PY  - 2020
DO  - 10.1111/ejh.13364
SN  - 0902-4441
UR  - https://hdl.handle.net/20.500.12105/23047
AB  - Objectives: Diffuse large B-cell lymphoma (DLBCL) is an aggressive heterogeneous lymphoma with standard treatment. However, 30%-40% of patients still fail, so we should know which patients are candidates for alternative therapies. IPI is the main...
LA  - eng
PB  - Wiley
KW  - Diffuse large B-cell lymphoma
KW  - International prognostic index
KW  - Prognosis
KW  - Score
KW  - Tumor score
KW  - Aged
KW  - Doxorubicin
KW  - Young Adult
KW  - Adult
KW  - Cyclophosphamide
KW  - Humans
KW  - Adolescent
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Middle Aged
KW  - Neoplasm Grading
KW  - Antineoplastic Agents, Immunological
KW  - Neoplasm Staging
KW  - Prognosis
KW  - Rituximab
KW  - Male
KW  - Female
KW  - Treatment Outcome
KW  - Vincristine
KW  - Lymphoma, Large B-Cell, Diffuse
KW  - Prednisone
KW  - Registries
KW  - Survival Analysis
TI  - Evaluation of the MD Anderson tumor score for diffuse large B-cell lymphoma in the rituximab era
TY  - research article
ER  -